Trial Profile
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib frontline therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Dec 2015
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 18 Dec 2015 New trial record